Short answer: no, not yet. Retatrutide is still in clinical trials and has not received FDA approval as of 2025. But the data coming out of those trials is unlike anything we have seen from a weight loss drug before, and that is why everyone is asking about it.
Here is everything you need to know, based on the actual research.
What Is Retatrutide and How Does It Work?
Retatrutide is a triple hormone receptor agonist. It targets three receptors at the same time: GLP-1, GIP, and glucagon. Most people have heard of GLP-1 drugs like Ozempic. Retatrutide does what those drugs do, and then adds two more mechanisms on top.
GLP-1 slows digestion and reduces appetite. GIP improves how your body handles insulin and fat storage. Glucagon increases energy expenditure, meaning your body burns more calories even at rest.
In my experience reviewing the research on metabolic drugs, the glucagon component is what makes retatrutide genuinely different. Every other drug in this class suppresses appetite. Retatrutide suppresses appetite and turns up your metabolic rate. That combination is what is driving the weight loss numbers we are seeing in trials.
Eli Lilly developed retatrutide, the same company behind Mounjaro and Zepbound. They know this space well, and the trial design reflects that.
When Will Retatrutide Be Approved by the FDA?
The most realistic estimate is 2026, possibly late 2025 if Phase 3 results come in strong and Eli Lilly moves fast on the submission. For those in Australia, understanding retatrutide pricing in Australia can help with planning.
Here is where things stand right now. Phase 2 trials completed in 2023 and the results were published in the New England Journal of Medicine. Phase 3 trials are currently running under the program name TRIUMPH. These are larger trials across more people and more conditions, including obesity, type 2 diabetes, and cardiovascular risk.
The FDA approval process after Phase 3 submission typically takes 12 months under standard review, or 6 months under priority review. Given the obesity epidemic and the strength of Phase 2 data, priority review is possible.
What I found when looking at the timeline is that Eli Lilly has been moving faster on retatrutide than they did with tirzepatide. They have the infrastructure, the regulatory experience, and a clear commercial incentive to get this to market. My read is 2026 is the realistic window, with any earlier approval being a bonus.
How Much Weight Can You Lose With Retatrutide?
The Phase 2 data showed an average of 24.2% body weight reduction over 48 weeks at the highest dose tested (12mg). That is not a typo.
To put that in context, semaglutide (Ozempic, Wegovy) produces around 15% weight loss. Tirzepatide (Mounjaro, Zepbound) produces around 20-22%. Retatrutide at 12mg produced 24.2% in the same timeframe.
The study involved 338 adults with obesity. Participants on the highest dose lost an average of 58 pounds over 48 weeks. Some participants lost more than 30% of their body weight.
What I saw in the data that stood out was the trajectory. Weight loss had not plateaued by week 48 in many participants. That suggests the ceiling may be even higher with longer treatment duration, which Phase 3 will help clarify.
These are not cherry-picked numbers. This is the published Phase 2 data from a peer-reviewed journal. The effect size is real.
How Does Retatrutide Compare to Ozempic and Mounjaro?
Here is a direct comparison based on published clinical data.
- Ozempic and Wegovy (semaglutide): GLP-1 agonist only. Average weight loss around 15% over 68 weeks in the STEP trials. Well established safety profile. FDA approved.
- Mounjaro and Zepbound (tirzepatide): Dual GLP-1 and GIP agonist. Average weight loss around 20-22% over 72 weeks in the SURMOUNT trials. FDA approved for obesity.
- Retatrutide: Triple GLP-1, GIP, and glucagon agonist. Average weight loss 24.2% over 48 weeks in Phase 2. Not yet FDA approved.
The pattern is clear. Each additional receptor target adds meaningful weight loss on top of the last. Retatrutide is the next step in that progression.
The side effect profile in Phase 2 was similar to other GLP-1 drugs. Nausea, vomiting, and diarrhea were the most common, mostly during dose escalation. Serious adverse events were low. The glucagon component did raise heart rate slightly in some participants, which is something Phase 3 is monitoring closely.
When I tried to find a meaningful downside in the Phase 2 data, the main one was that the drug is newer and we have less long-term safety data. That is not a reason to dismiss it. It is just the honest reality of where we are in the research timeline.
Can I Join a Retatrutide Clinical Trial?
Yes, and this is the only way to access retatrutide right now.
The TRIUMPH Phase 3 trials are actively recruiting in multiple countries including the United States, Australia, and across Europe. You can search for open trials at ClinicalTrials.gov using the search term retatrutide or LY3437943, which is the compound identifier.
To be eligible for most trials you generally need to meet criteria like a BMI of 30 or above, or 27 or above with a weight-related health condition like type 2 diabetes or high blood pressure. Each trial has its own specific inclusion and exclusion criteria.
What I found when looking at the trial landscape is that there are multiple sub-studies running, not just the main obesity trial. There are trials focused on type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular outcomes. If you do not qualify for one, you may qualify for another.
Joining a trial means you may receive the drug, or you may receive a placebo. You will not know which. But you will receive close medical monitoring, regular check-ins, and all study-related care at no cost. For many people that is a reasonable trade-off.
Three Things Most People Get Wrong About Retatrutide
Most coverage of retatrutide focuses on the weight loss numbers and stops there. Here are three things worth understanding that most articles skip.
- The glucagon mechanism changes the body composition picture. GLP-1 drugs cause weight loss but some of that loss is muscle mass. The glucagon receptor activation in retatrutide appears to preferentially drive fat loss, including visceral fat. The Phase 2 data showed significant reductions in liver fat and waist circumference beyond what the scale number alone suggests. This matters because visceral fat is the fat that drives metabolic disease, not just the number on the scale.
- Retatrutide may work differently in people who have stopped responding to other GLP-1 drugs. The triple mechanism means it is not just a stronger version of the same thing. It is a different mechanism. Early anecdotal reports from trial participants who had previously used semaglutide suggest meaningful additional response. Phase 3 will give us cleaner data on this.
- The approval timeline is not the only timeline that matters. Even after FDA approval, access depends on insurance coverage, prescribing guidelines, and supply. Tirzepatide was approved in 2022 and supply shortages lasted well into 2024. Planning for retatrutide availability means planning for that reality, not just the approval date.
What Should You Do While Waiting for Retatrutide?
If you are waiting for retatrutide because you have struggled with weight loss and nothing else has worked, that is a reasonable position. The data supports the idea that this drug may produce results that current options do not.
But waiting is not a neutral act. The research on obesity is clear that earlier intervention produces better long-term outcomes. Metabolic health, cardiovascular risk, and joint health all respond to weight loss regardless of how that loss is achieved.
In my experience looking at how people approach this, the ones who do best are the ones who use the waiting period to build the habits that make any drug more effective. Sleep, protein intake, resistance training, and stress management all influence how well GLP-1 class drugs work. They reduce muscle loss during rapid weight loss. They improve the metabolic environment the drug is working in.
If you want structured support while you wait, or while you are on any weight loss medication, online personal trainer makes a real difference. The drug handles appetite and metabolism. The coaching handles the behavior and body composition side. Those two things together produce better outcomes than either one alone.
FAQ
Is retatrutide available yet?
No. Retatrutide is not FDA approved and is not available by prescription as of 2025. It is only accessible through clinical trials.
What is retatrutide?
Retatrutide is a triple agonist drug developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously to reduce appetite and increase energy expenditure.
When will retatrutide be approved?
The most realistic estimate based on current Phase 3 trial timelines is 2026. An earlier approval is possible but not guaranteed.
How much weight does retatrutide cause you to lose?
Phase 2 data showed an average of 24.2% body weight reduction over 48 weeks at the 12mg dose. That is approximately 58 pounds on average for participants in the trial.
Is retatrutide better than Ozempic?
Based on Phase 2 data, retatrutide produces greater weight loss than semaglutide. Whether it is better for any individual depends on their specific health profile, which a doctor needs to assess.
How do I join a retatrutide clinical trial?
Search ClinicalTrials.gov for retatrutide or LY3437943 to find currently recruiting trials. Eligibility typically requires a BMI of 30 or above, or 27 or above with a related health condition.
Does retatrutide cause muscle loss?
All rapid weight loss carries some risk of muscle loss. The glucagon component of retatrutide appears to preferentially target fat, but resistance training and adequate protein intake remain important during treatment.
